Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Ion Trap Mass Spectrometer

By Drug Discovery Trends Editor | September 30, 2009

Thermo Fisher Scientific Inc. released a new application note that illustrates the superior capabilities of dual-pressure linear ion trap technology for the investigation of proteome dynamics. The application note assessed the performance of the newly launched Thermo Scientific LTQ Velos ion trap mass spectrometer for the analysis of a complex, multi-organ peptide digest of Caenorhabditis elegans (C. elegans). The LTQ Velos ion trap mass spectrometer offers improvements in speed and sensitivity, providing greater coverage in the analysis of complex peptide mixtures and increasing the confidence of protein identification at low sample levels. “Novel Dual-Pressure Linear Ion Trap Mass Spectrometer Offers Breakthrough Performance in Proteomics Experiments” is available for download via www.thermo.com/velos462.

Tandem mass spectrometry, particularly using linear ion traps and trap-based hybrid mass spectrometers, has become a leading technology for peptide and protein identification.  The preference for this technology is due to its ease of use as well as its superior MS and MS/MS performance. The multiple fragmentation techniques available on the LTQ Velos enable more confident sequence assignment and post-translational modification (PTM) identification. Faster scan rates also significantly reduce cycle times, increasing the number of proteins and peptides identified.

The application note describes an effective method for the analysis of peptides and proteins using the LTQ Velos mass spectrometer. To compare and benchmark performance, the company ran analyses on both a Thermo Scientific LTQ XL linear ion trap mass spectrometer and a quadrupole time-of-flight (Q-TOF) mass spectrometer. The study used data-dependent tandem acquisition methods, and the team separated a proteolytic digest of C. elegans using reverse phase chromatography for each LC-MS/MS run. The analysis revealed that the LTQ Velos identifies ~240 percent more proteins and ~130 percent more distinct peptides from a highly complex sample than is possible with the Q-TOF.

For more information about the Thermo Scientific LTQ Velos or to obtain a copy of the application note, please call 1-800-532-4752, e-mail analyze@thermo.com or visit www.thermo.com/velos462.

Thermo Fisher Scientific Inc.


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE